3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
11
Breast Neoplasms
10
Neoplasms
4
Osteoporosis
2
Melanoma
2
Cardiovascular Diseases
2
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Smoldering Multiple Myeloma
1
Regional Osteoporosis as a Result of Chemotherapy
1
Primary Ovarian Insufficiency
1
Polycystic Ovary Syndrome
1
Paraganglioma, Extra-Adrenal
1
Pain
1
Oropharyngeal Neoplasms
1
Neoplasms, Plasma Cell
1
Neoplasm Metastasis
1
Monoclonal Gammopathy of Undetermined Significance
1
Metabolic Syndrome
1
Menstruation Disturbances
1
Lymphedema
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Hematopoietic and Lymphoid System Neoplasm
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Depression
1
Cognitive Dysfunction
1
Interventions
pembrolizumab
37
Gemcitabine
29
Nivolumab
20
Cisplatin
19
atezolizumab
15
avelumab
14
Docetaxel
13
enfortumab vedotin
10
Carboplatin
10
durvalumab
9
Magnetic Resonance Spectroscopy
9
Ipilimumab
8
Paclitaxel
7
Pemetrexed
6
toripalimab
5
cabozantinib
5
Fluorodeoxyglucose F18
5
sacituzumab govitecan
4
cabazitaxel
4
Taxes
4
vinflunine
3
tremelimumab
3
pemigatinib
3
X-Rays
3
Standard of Care
3
Specimen Handling
3
Radiotherapy
3
Mitomycin
3
Immunotherapy
3
Immunoglobulin G
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Transitional Cell
×
Absorptiometry, Photon
×
Clear all
NCT01490437
2014-09-25
PECULIAR
Asan Medical Center
Phase 2
Completed
42 enrolled